Skip to main content
Normal View

Medicinal Products

Dáil Éireann Debate, Tuesday - 28 May 2019

Tuesday, 28 May 2019

Questions (302, 303, 304)

Louise O'Reilly

Question:

302. Deputy Louise O'Reilly asked the Minister for Health if a third party reviewer of the drugs approval and procurement process has been appointed; if so, the name of the reviewer; and if they have commenced their work. [22831/19]

View answer

Louise O'Reilly

Question:

303. Deputy Louise O'Reilly asked the Minister for Health if the review of the drugs approval and procurement process will have a consultation with clinicians, patients or industry. [22832/19]

View answer

Louise O'Reilly

Question:

304. Deputy Louise O'Reilly asked the Minister for Health if the review of the drugs approval and procurement process will include specific recommendations. [22833/19]

View answer

Written answers

I propose to take Questions Nos. 302 to 304, inclusive, together.

The Department recently completed a tender process for a review of the HSE reimbursement and pricing decision-making process. Mazars has been appointed as the consultancy firm to complete this review.

The review is expected to be completed within three months of commencement and consideration will be given, in due course, to publication of a final report.

Although it is not specifically included in the terms of reference, consideration will be given to consultation with relevant stakeholders.

The review will make recommendations, as considered appropriate, in respect of any required improvements to the HSE’s systems, structures, processes, governance arrangements or use of specialist resources in respect of the review.

In making its recommendations, the review will have regard to best practice regarding the procurement of medicines, the conduct of high-value commercial negotiations, governance, organisational structures, skill-mix and oversight.

Top
Share